Your browser doesn't support javascript.
loading
Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance.
Bergamini, Bianca; Seneschal, Julien; Meyers, Kristin J; Durand, Frederick; Haladyj, Ewa; Espinosa, Gerard; Thyssen, Jacob P.
Afiliação
  • Bergamini B; Eli Lilly and Company, Indianapolis, IN, USA.
  • Seneschal J; Department of Dermatology, National Reference Center for Rare Skin Disorders, CNRS, UMR5164, ImmunoConCept, University of Bordeaux, Bordeaux, France.
  • Meyers KJ; Eli Lilly and Company, Indianapolis, IN, USA.
  • Durand F; Eli Lilly and Company, Indianapolis, IN, USA.
  • Haladyj E; Eli Lilly and Company, Indianapolis, IN, USA.
  • Espinosa G; Department of Autoimmune Diseases, Hospital Clinic, Universitat de Barcelona, Barcelona, Catalonia,Spain.
  • Thyssen JP; Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Br J Dermatol ; 189(6): 767-769, 2023 11 16.
Article em En | MEDLINE | ID: mdl-37595142
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azetidinas / Resultado da Gravidez Tipo de estudo: Screening_studies Limite: Female / Humans / Pregnancy Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azetidinas / Resultado da Gravidez Tipo de estudo: Screening_studies Limite: Female / Humans / Pregnancy Idioma: En Ano de publicação: 2023 Tipo de documento: Article